Contribute Try STAT+ Today

MOUNTAINSIDE, N.J. — On election night, Bob Hugin insisted it wasn’t his past as a pharmaceutical executive that did him in.

Incessant attacks from his Democratic opponent, $3.5 million worth of ads labeling him “the guy who made a killing” by raising drug prices, and a pharma-focused interview on a nationally syndicated radio show beg to differ.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Was going to vote for Hugin. After a month of being conflicted I decided to vote for Hugin but at the last minute voted for Menendez because of Trump. I know Trump is a low life and in the end figured Hugin loves him so he must be in the gutter with the editor and chief reporter for the Fake News (all editions). I know Menendez is a thief but I’ll stick with the thief I know rather than the one I don’t. Al least I know Menendez will fight for healthcare, prescription drugs and social security and education. B

Comments are closed.